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SUMMARY Tissue-engineered biological dressings offer promise in the 
treatment of burns, chronic ulcers, donor site and other surgical wounds, and 
a variety of dermatologic conditions.  Despite this promise, cellular tissue-
engineered products such a Dermagraft® and Apligraf® have suffered 
setbacks in recent years with a lower market share than the commercial 
promoters of these products anticipated. AlloDerm acellular dermal matrix, 
an older technology than these cell-based products, has made strong 
progress in winning over clinicians in various disciplines.  Similarly, Integra 
Bilayer Matrix Wound Dressing (BMWD) continues to gain acceptance 
beyond its original burn audience. A review on the products is offered.  
KEY WORDS: wound healing; burns; plastic and reconstructive surgery; 
tissue-engineering; artificial skin
INTRODUCTION
 The term tissue-engineering has numerous 
definitions (1). However, a broad definition that 
can be formulated is “methods that promote bio-
logic repair or regeneration of tissues and organs 
by providing signaling, structural, cellular or tis-
sue elements”. The arsenal of tissue-engineering 
can include biomaterials, cells, growth factors and 
other signaling molecules, and in some instances 
engineering components such as pumps, tubes, 
bioreactors, and oxygenators.
 Tissue-engineered biological dressings offer 
promise in the treatment of burns, chronic ulcers, 
donor site and other surgical wounds, and a variety 
of dermatologic conditions. Despite this promise, 
cellular tissue-engineered products such as Der-
magraft® and Apligraf® have suffered setbacks 
and have not achieved the anticipated adoption 
by clinicians. Outside of the United States, compli-
cated regulations for approval of products contain-
ing allogeneic cells, high pricing and challenges in 
obtaining reimbursement make the future of such 
products uncertain.
 On the other hand, AlloDerm acellular dermal 
matrix, an older technology, has made strong 
progress in winning over clinicians in various dis-
ciplines. Similarly, Integra Bilayer Matrix Wound 
Dressing (BMWD) continues to gain acceptance 
beyond its original burn audience. In light of this, a 
review of the evolving uses of both of these acel-
lular dermal replacement scaffolds is offered.
 The need of dermal substitutes
 The skin is the largest organ of the human body. 
It is the first line of defense against infection, pre-
vents dehydration and helps regulate body tem-
perature through changes in blood flow and sweat 
production. It is also a major sensory organ. The 
skin’s continuity and integrity can be compromised 
due to trauma, including surgery, or can become 
damaged secondary to an underlying pathology 
such as reduced venous or arterial circulation. 
Wounds can afflict only the epidermis (surface 
wounds) or can extend through the thicker dermal 
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layer (partial- or full-thickness wounds). Generally, 
the deeper the wound, the greater its biologic and 
clinical significance.
 Skin consists of two distinct layers: the epider-
mis and the dermis. The thin epidermis comprises 
rapidly dividing keratinocytes, which produce ker-
atin, a strong structural protein. The topmost layer 
of the epidermis is stratum corneum, a thin wa-
ter-tight layer of dead, flattened cells. The thicker 
dermis, situated below the epidermis, is a complex 
association of fibroblasts and extracellular matrix, 
accounting for the skin’s mechanical integrity and 
elasticity. The skin’s blood vessels, nerve fibers 
and lymphatics all reside within this layer. The 
epidermis is nourished by diffusion of small mol-
ecules from the dermis. The skin’s appendages 
(i.e. hair follicles and sweat glands), traverse both 
levels. Beneath the dermis is the hypodermis, a 
loose connective tissue comprising primarily adi-
pose tissue.
 Wounds of different etiology, depth and surface 
area must be treated differently and have dis-
similar clinical prognoses. Normal wound healing 
originates with regeneration from epidermal cells 
in the appendages of the deep dermal layer such 
as hair follicles. In-growth from wound edges also 
occurs but is ineffective for wounds larger than 
a few centimeters, and wound healing without a 
dermal layer results in contracture. It can be con-
cluded that large or deep wounds and wounds that 
obliterate the skin’s appendages are of particular 
clinical challenge.  
 The ideal synthetic wound dressing or biologic 
skin substitute should have the following charac-
teristics, enumerated for the most part by Pruitt 
and Levine more than twenty years ago (2), and 
added to by ourselves and others (3):
• absence of antigenicity
• tissue compatibility
• absence of local or systemic toxicity
• impermeability to exogenous microorganisms
• water vapor transmission similar to normal 
skin
• rapid and sustained adherence to wound sur-
face
• conformity to surface irregularities
• elasticity to permit motion of underlying tissue
• resistance to linear and shear stresses
• tensile strength to resist fragmentation
• inhibition of wound surface flora and bacteria
• biodegradability (for permanent membranes)
• translucent properties to allow direct observa-
tion of healing
• reducing heal-time
• not increasing the rate of infection
• minimizing patient discomfort
• minimizing nursing care of wound
• patient acceptance
• low cost
• long shelf life, minimal storage requirements
Description and history of AlloDerm
 AlloDerm® (AlloDerm® is a registered trademark 
of Lifecell Corporation, Branchburg, NJ) consists 
of a freeze-dried extracellular tissue matrix de-
rived from donated cadaver skin, which, according 
to the manufacturer, is supplied by the US Ameri-
can Association of Tissue Banks-compliant tissue 
banks (4). AlloDerm is regarded by the Food and 
Drug Administration (FDA) as a minimally manipu-
lated human tissue (5). “Minimal manipulation” 
is defined as processing that does not alter the 
characteristics of the tissue relating to its utility for 
reconstruction, repair, or replacement. Another 
criterion is “homologous use”, defined as the use 
of cellular or tissue-based products for the same 
basic function that it fulfils in its native state, at 
a location where such structural function normally 
occurs. As such, when used for the replacement 
of integumental tissue, AlloDerm does not require 
the filing and approval of a PMA or 510k, which is 
otherwise required of medical devices. However, 
if sold for a non-homologous use such as dural 
replacement, AlloDerm is regulated as a medical 
device and such filing and FDA approval would be 
required.  
 During the processing of AlloDerm, the epider-
mis and any cellular elements in the dermis are 
removed by exposure to a hypertonic solution, 
leaving behind a matrix of extracellular material 
including an intact basement membrane, collagen 
fibers, elastin filaments, and ground substance 
such as hyaluronan and proteoglycan. The integ-
rity of the basement membrane complex, normal 
collagen bundle and banding patterns, and the 
absence of cellular material have been confirmed 
with electron microscopy (6). Importantly, the 
resulting matrix, which retains the essential bio-
chemical and structural properties of human der-
mis, is non-antigenic (conventional skin allograft 
is ultimately rejected). The product is treated with 
detergent (0.5% SDS) to inactivate viruses and 
cryoprotectants (dextran, sucrose, raffinose and 
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EDTA) prior to freeze-drying (7). AlloDerm is pro-
cessed under aseptic conditions but there is no 
terminal sterilization, as both radiation and ethyl-
ene oxide would damage the matrix.  
 To use AlloDerm, it is aseptically removed from 
its foil packaging and placed in a saline bath. The 
manufacturer suggests that warming the saline to 
37 °C but not above accelerates the process. The 
tissue should be submerged completely and soaked 
for five minutes or until the backing separates. After 
this, the AlloDerm is transferred to a second bath 
and soaked until it is fully hydrated, as evidenced 
by its being soft and pliable. This can take up to 
40 minutes for thicker pieces. The graft should be 
used within four hours of preparation. When used 
for grafting, it should be placed with the dermal side 
down (smooth and shiny) and basement membrane 
side up (rough and dull) (8).
 When placed in a wound, AlloDerm is populated 
by circulating cells, which establish a neovascula-
ture and elaborate new extracellular matrix while 
incorporating the AlloDerm material. The graft is 
ultimately remodeled into the tissue with char-
acteristics of the site into which it has been im-
planted (9). However, having no epidermal layer, it 
provides a limited barrier function. When used as 
a graft, it must be dressed with a thin autograft as 
well as moisture-retaining dressings.
 Alloderm is readily available and has a shelf life 
of two years under refrigeration. It is available in a 
variety of configurations, ranging from 2 to 72 cm2 
in area and 0.17 mm to 1.8 mm (and up) in thick-
ness (10). 
 When the famous bank robber Willie Sutton 
was asked why he robbed banks, he simply re-
plied: “Because that’s where the money is” (11). 
It is not surprising then that the earliest focus for 
AlloDerm and other tissue-engineered skin prod-
ucts was in burns. It was thought that it was where 
the skin was needed. Although the most obvious 
of uses, it is also the smallest of contemplated ap-
plications today.
 The commercialization of AlloDerm as a dermal 
replacement in the grafting of full-thickness and 
deep partial-thickness burns began in December 
1993. Since 1995 it has also been used in peri-
odontal surgery and reconstructive plastic surgery. 
The acellular matrix is also sold under the brand 
names Repliform® and Graftjacket® for urologic 
and orthopedic procedures, respectively.  It is also 
available in a micronized form for injection termed 
Cymetra®. Repliform, Graftjacket and Cymetra are 
beyond the scope of this article.
A review of clinical applications
 AlloDerm in burns
 Each year in the United States, 696,000 people 
visit the emergency room due to burns (12), result-
ing in 50,000 hospitalizations (13). The majority of 
these cases, those in which the burns are not ex-
tensive, do not pose a clinical challenge. These 
patients usually have sufficient healthy skin from 
which autograft can be harvested.  
 However, sometimes sufficient healthy material 
is unavailable for autograft or the added trauma of 
creating a donor wound cannot be tolerated. Ac-
cording to the American Burn Association (14), the 
average size of a burn injury admitted to a burn 
center is about 14% of total body surface area 
(TBSA). Burns of 10% TBSA or less account for 
54% of cases, while burns of 60% TBSA or greater 
account for just four percent of admissions.  
 The subset of severely injured patients repre-
sents the most compelling application in burns for 
tissue-engineered products. There also are cer-
tain rare skin disorders such as toxic epidermal 
necrolysis (TEN) and epidermolysis bullosa (EB), 
in which conditions resemble those that result from 
severe burns. These too may benefit from the ap-
plication of tissue-engineered biologic dressings. 
For example, AlloDerm and ultrathin epidermal 
graft have been used in a case of purpura fulmi-
nans, a syndrome of intravascular thrombosis of 
the skin with hemorrhagic infarction (15).
 Deep partial-thickness and full-thickness burns 
typically require autografting to achieve healing. 
In severe burns, a temporary covering is often em-
ployed as a bridge to autografting. Allograft from 
cadaver skin has been the traditional choice, pro-
viding biologic closure, reduction in pain and de-
creased fluid loss. The immune suppression ob-
served in severely burned patients prevents rapid 
rejection of allograft but rejection ultimately oc-
curs, typically within days to weeks, necessitating 
repeat allografting if the patient is not yet ready for 
autografting. The advantages of allograft are tem-
pered by variable supply, the possibility of disease 
transmission, although careful screening of do-
nors substantially reduces this risk, and bleeding 
provoked upon removal. Porcine xenograft such 
as E-Z Derm (Brennen Medical, St. Paul, Minne-
sota) is sometimes used as a temporary wound 
covering. It provides similar benefits as allograft 
but is rejected or “ejected” more rapidly (16).
 Yet, AlloDerm is not considered a replacement 
for allograft as a temporary dressing. Rather, it 
is a permanent dermal replacement facilitating 
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thinner autografts (17,18) with a resultant decrease 
in donor site morbidity. In many applications, lim-
ited autograft availability necessitates maximizing 
the available resource in the form of thinner grafts 
in which donor sites can be reharvested sooner, 
meshing of the graft and using cultured epidermal 
cells. If the method chosen (e.g., a very thin split 
thickness skin graft) does not supply a solid der-
mal layer, wound contraction, scarring and long-
term disability can result.
 Under best of circumstances autografting cre-
ates a donor site, which is itself a site of potential 
infection and fluid loss. The donor site is gener-
ally a partial-thickness wound, but sometimes 
it extends no deeper than the epithelium. Donor 
wounds are associated with pain, discomfort, fluid 
collection and the ever-present possibility of infec-
tion. Being able to take a thinner autograft reduces 
donor site wounds, leads to more rapid donor site 
healing, and enables more rapid donor site re-
cropping procedures. This can ultimately result in 
a reduced length of hospital stay and more rapid 
patient rehabilitation.      
 As with any graft, the wound bed must be pre-
pared appropriately prior to AlloDerm placement. 
This means a clean, viable, vascularized tissue 
with adequate hemostasis. In the case of severe 
burns, this can mean debridement to muscular 
fascia. If there remains even a small amount of 
bleeding, the AlloDerm should be meshed, as 
should the overlying autograft (8). 
 AlloDerm is often used as a dermal layer in the 
grafting of major joints, where it helps prevent scar 
contracture. Contractures are associated with the 
loss of limb mobility and often necessitate recon-
structive surgery. Two case studies in burns have 
been first reported by Wainright (6). In a 67-patient 
study in full-thickness or deep partial-thickness 
burns, Alloderm plus a thin split thickness skin graft 
(STSG) was deemed equivalent to a thicker split 
thickness skin graft used alone, in a within patient 
design (19). In a report on three patients with full-
thickness burns of distal extremities, Lattari et al. 
report on the use of AlloDerm with ultrathin auto-
graft with “good to excellent” results in the range of 
motion, grip strength and fine motor coordination 
(17). In a study of six children, ten burn sites were 
grafted with AlloDerm and thin autograft, and ten 
matched sites on each patient were grafted with 
a thicker autograft. There were no significant dif-
ferences between the two procedures as gauged 
by epthelialization and the Vancouver Scar Scale 
(20). At follow-up at a mean of 43.7 weeks, there 
was still no difference in the Vancouver Scar Scale 
score between the two procedures (21).
 The ability to harvest a very thin autograft is 
particularly important in the elderly, in which har-
vesting the donor site often creates a new full-
thickness defect due to thinness of the underlying 
skin, often discouraging operative wound debride-
ment and autografting in this population. In a study 
(18) comparing 10 elderly burn patients receiving 
Alloderm with historic control, the donor site heal-
ing time was substantially reduced with Alloderm 
(12 days vs. 18 days), while graft take was the 
same in the two groups. However, the use of Al-
loDerm did not result in improved mortality.
 AlloDerm in reconstructive surgery
 Today, AlloDerm is by far more frequently used 
in reconstructive surgery than in burns, typically as 
a soft tissue implant, most commonly in skin can-
cer excision, scar revision, oral resurfacing, cleft 
palate repair, oculoplasty, revision rhinoplasty, and 
septal perforation repair (22). As each procedure 
is different, the literature is often scant on any par-
ticular use. Many of these procedures can also be 
performed using autograft, xenograft or synthetic 
alloplastic materials. In cases where autograft can 
be harvested in sufficient amounts and without un-
due trauma to the patient, it is often preferred. Fat, 
dermis, fascia, cartilage, bone, and muscle are 
all used. In many cases, however, the available 
autograft is insufficient or the scarring and donor-
site trauma are unacceptable. Alloplastic materials 
suffer from poor tissue adherence, elicit a foreign-
body reaction, and are at risk of extrusion (23). 
Xenograft bovine collagen is often used as well. 
However, the material is rapidly resorbed and is 
antigenic in some individuals.    
 AlloDerm in head and neck surgery
 In one series, 13 of 17 patients with symptom-
atic anterior nasal septal perforations that had 
failed conservative treatment had a successful 
repair of the perforation with a closed endoscopic 
repair using AlloDerm and an anteriorly based in-
ferior turbinate flap (22). In primary cases of septal 
perforation, the avoidance of a donor site, which is 
usually necessary to harvest temporalis fascia or 
pericranium, is a notable advantage. In a series 
of 12 patients receiving AlloDerm as an interposi-
tional graft for repair of a nasal septal perforation, 
11 of 12 had successful outcomes with complete 
closure of the perforation (24). AlloDerm has been 
successfully used for nasal contouring but was 
limited by partial absorption in some patients and 
induration of the graft area (25). In three patients 
with unilateral partial or full-thickness nasal septal 
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mucosal defects, AlloDerm was used with excel-
lent results reported at two-month follow up (26). 
AlloDerm has also been reported to perform well 
at two-year follow up when used to correct dorsal 
nasal irregularities that occurred postoperatively, 
such as thinning of the nasal skin, bony irregu-
larities and adhesion of dorsal skin to bone (27). 
AlloDerm use in conjunction with a high density 
polyethylene implant has been described in a ma-
jor saddle nose deformity when sufficient autograft 
is unavailable (28).
 AlloDerm has been described as “an ideal ma-
terial for closure of skull base defects” eliminating 
the need of an autogeneic graft and donor site (29). 
Nine of nine cerebrospinal fluid leaks were suc-
cessfully repaired as were 22 of 24 sellar repairs 
after trans-sphenoidal hypophysectomy.  Impor-
tantly for head and neck oncologic surgery, graft 
thickness and neovascularization are not adversely 
affected by prior external beam radiation, as dem-
onstrated in a rat study (30). Even direct external 
beam radiation of AlloDerm has relatively modest 
effects, hindering recellularization in the early post-
treatment period but normalizing by 12 weeks (31). 
Neovascularization, however, remained reduced in 
the irradiated group even at 12 weeks, but without 
effect on ultimate graft survival.
 AlloDerm is considered a good alternative to 
temporalis fascia, the gold standard, in tympano-
plasty when no temporalis fascia can be located 
(e.g., revisions) or when it is desirable to avoid a 
separate donor site during transcanal approach 
(32). In a retrospective analysis comparing 20 pa-
tients receiving AlloDerm with 20 patients receiv-
ing temporalis fascia for tympanic grafting, there 
were no graft failures in either group and no statis-
tically significant between group difference in re-
sidual conductive hearing loss (33). In a series of 
24 patients, 17 with simple perforations and seven 
with chronic otitis media with cholesteatoma, the 
success rate with AlloDerm in achieving closure 
of the tympanic membrane was 87.5%, equivalent 
to that of temporal fascia, in the opinion of the au-
thor (34). In seven patients with traumatic perfo-
rations of the tympanic membrane that failed to 
close spontaneously, AlloDerm was placed over 
the defect as an in-office procedure. Six of seven 
patients experienced complete healing and an im-
provement in hearing (35). Similarly, when suffi-
cient mastoid fascia is unavailable, AlloDerm has 
been used to cover mastoid defects created by ca-
nal wall down mastoidectomy, a procedure used 
to address cholesteatoma or chronic ear disease. 
The creation of a dry, well-epithelialized mastoid 
bowl is cited as one of the challenges in this pro-
cedure (36).   
 In a 30-patient controlled clinical study, Allo-
Derm was used as an interpositional barrier to re-
duce the incidence of Frey’s syndrome following 
superficial parotidectomy (37). In a similar 64-pa-
tient study, AlloDerm as an interpositional barrier 
reduced the subjective (3.1% vs. 9.3%) and objec-
tive (0% vs. 40%) incidence of Frey’s disease, but 
carried a higher risk of complication (9% vs. 25%), 
notably seroma formation (38).  
 In a seven-patient series, AlloDerm has been 
deemed effective for repair of wide clefts of the 
hard and soft palate when applied deep to the oral 
mucosa (39). It was also used in 10 patients to 
reconstruct large pharyngeal defects in which pri-
mary closure was not possible. Functional results 
were deemed excellent, although two patients de-
veloped fistulas that resolved with conservative 
management (40).
 AlloDerm has been used on the donor site cre-
ated by the harvest of a radial forearm free flap, a 
preferred tissue source for head and neck recon-
struction. Partial graft loss with exposure of flexor 
tendons is a common complication. In a retro-
spective chart review comparing AlloDerm to split-
thickness skin graft from the thigh, AlloDerm treat-
ed patients required considerably longer healing 
time than those undergoing skin grafting (12-16 
weeks vs. 4-6 weeks) (41). In a 52-patient study, 
AlloDerm was used in place of split thickness skin 
grafting for radial forearm free flap coverage. Full 
range of hand motion was possible in three days, 
but complete healing took 8 to 12 weeks. Contrac-
ture was minimal and the only complication was 
seroma formation in five patients (42).  
 The use of AlloDerm has been reported in 11 
patients for augmentation of soft-tissue defects 
or scarring of the face, where it was deemed an 
“excellent augmentation material” and was with-
out significant complications (43). In a report on 
12 patients receiving AlloDerm for lip augmenta-
tion, all were pleased with their results at an av-
erage follow up of seven months (44). Initial in-
duration eventually subsided and the graft was 
reported to take on a natural feel. Rolled up like 
a cigarette, AlloDerm has been used for lip aug-
mentation with “extreme satisfaction” expressed 
by the patient (45). AlloDerm in combination with 
fat autograft has been reported to yield superior 
results to fat autograft alone when used for lip 
augmentation (46).
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 AlloDerm has also been reported in one case 
to repair a depressed tracheostomy scar with a 
tracheal tug (47), and in another to avoid a de-
pressed tracheostomy scar (48). A case study has 
been reported describing its use in reconstructing 
a calcaneal defect, along with full-thickness skin 
grafting at a later stage (48).   
 AlloDerm in neurosurgery
 AlloDerm has been used in various types of 
neurosurgical reconstruction (36,49), often as a 
dural substitute (49-51), typically when sufficient 
temporalis fascia is unavailable, reportedly with 
good results. It has even been used for in utero re-
pair of myelomeningocele (53). The product can-
not be promoted as a dural substitute by LifeCell 
(54) as such a use would require regulation as a 
medical device and not banked human tissue.  
 AlloDerm in ophthalmic surgery
 In 21 procedures, thick AlloDerm grafts were 
deemed comparable to hard palate grafts in pos-
terior and middle lamellae reconstruction to cor-
rect lower eyelid retraction, as compared with his-
toric control (55). In a separate 19 graft study, Allo-
Derm, when used as a spacer graft in lower eyelid 
surgery, contracted significantly more than hard 
palate mucosa autograft (57% vs. 16%) but was 
still associated with a high rate of clinical success, 
except when used for a mildly contracted socket, 
in which only two of five had adequate results (56). 
A retrospective review has been published of 105 
cases of AlloDerm use in 63 patients for various 
ophthalmic and reconstructive procedures, pri-
marily as a posterior lamellar conjunctival spacer 
graft in the lower lid (92 cases), but also as upper 
eyelid posterior lamellar conjunctival spacer graft 
(4 cases), lower eyelid conjunctival spacer graft in 
anophthalmic contracted socket (2 cases), and as 
a soft tissue interpositional graft (5 cases) (57). All 
105 cases were reported to exhibit improvement 
following the procedure with no complications at-
tributable to AlloDerm. A retrospective 23-patient 
series similarly concluded that AlloDerm was an 
“excellent barrier and reconstructive grafting ma-
terial” when used in a variety of ophthalmic plastic 
applications (58).
 Looking forward in this indication, autogeneic 
conjunctival keratinocytes were recently grown 
on AlloDerm in a serum-free system, offering the 
promise of an implant sufficiently rigid for eyelid 
reconstruction with the addition of a conjunctival 
layer to minimize mucosal irritation (59).
 AlloDerm in general reconstructive proce-
dures and complex hernia repair
 AlloDerm has been used successfully as the 
base for a latissmus dorsi flap in a complex chest 
wall defect in a 61-year-old woman following re-
section of a sarcoma leaving a 20 cm x 20 cm soft 
tissue defect (60). It has been used to repair vari-
ous breast implant-related complications, notably 
capsular thinning and implant rippling, with mostly 
good results (61). It has been indicated by some 
that AlloDerm and cultured epidermal autograft 
are preferred for the coverage of aplasia cutis con-
genital (62). 
 AlloDerm has recently become popular for 
complex hernia repair (9,63,64). In fact, Lifecell re-
ports that the 64% growth in AlloDerm use in 2004 
versus 2002 was primarily driven by its use in this 
indication (65). The success of one author in early 
studies led him to adopt AlloDerm in all subse-
quent abdominal wall and breast reconstruction 
repairs (9). In a report on 44 patients receiving Al-
loDerm for complicated incisional hernia repair or 
transverse rectus abdominis musculocutaneous 
(TRAM) flap surgery, all were alive with no clinical 
infection or reports of bowel obstruction or fistula 
at a mean follow up of 20 months. Two patients 
developed seromas, three experienced postoper-
ative infections, and two had wound dehiscence.   
 An additional benefit to the use of AlloDerm in 
this application may be reduced adhesion forma-
tion as compared with polypropylene mesh alone 
(66) or Gore-Tex, as demonstrated in animal mod-
els (67). It is reported to perform as effectively as 
Gore-Tex in mechanical strength at one month in 
a rabbit ventral hernia model and to become well 
vascularized in that interval (67). It has also been 
used in conjunction with fibrin glue, in the context 
of a peritoneal cavity left open for controlling ful-
minant intra-abdominal sepsis, to patch intestinal 
deserosalizations (n=2) and to close an intestinal 
fistula (n=1) (68). It is thought to be more resistant 
to infection than a prosthetic material (9). 
 AlloDerm – summary and conclusion
 AlloDerm offers several advantages for soft 
tissue augmentation in dermatology, dermatosur-
gery, and plastic and reconstructive surgery. It is 
non-antigenic, integrates quickly into the patient’s 
own tissue, is available off-the-shelf and allows for 
a thinner donor-site wound.  It is relatively resistant 
to infection as compared with synthetic materials, 
and has been used successfully in contaminated 
environments (69). It is pliable and has attractive 
handling characteristics.  
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 Absorption of the product is its largest liabil-
ity (56,70). Ten volunteers participated in a study 
comparing AlloDerm with Zyplast (INAMED Aes-
thetics, Santa Barbara, California), a gluteralde-
hyde cross-linked bovine injectable type I colla-
gen. Each subject had both materials implanted, 
one behind either ear. About 20% of AlloDerm was 
noted to remain at six-month follow up, as deter-
mined by digital photographic analysis of the sur-
face area and lateral projection of the implant. This 
residual amount remained stable at 12-month fol-
low up, whereas Zyplast was completely resorbed 
by six months (71,72).  
 Absorption, particularly in plastic and recon-
structive procedures, must be anticipated and 
corrected for in advance to avoid a cosmetically 
undesirable outcome. This requires a certain 
amount of guesswork by the surgeon as to how 
much of the implanted material will remain. In 58 
patients receiving AlloDerm for nasal contouring, 
45% showed signs of greater than 50% absorp-
tion. This can result in under-correction of the de-
formity if the surgeon does not compensate for it. 
However, in 20 patients followed for two or more 
years, AlloDerm was noted to be stable between 
years one and two. This indicates that if the ini-
tial absorption can be corrected for at the time of 
surgery by implanting extra material, stable results 
can still be achieved (25). Similarly, a possible 
15%-20% shrinkage, which remained stable after 
4-6 weeks, has been reported when AlloDerm is 
used for lip augmentation (44). Rolled or stacked 
AlloDerm is specifically noted to have unpredict-
able absorbtion (59). But certainly not all clinical 
investigators have been troubled by this problem 
(27), particularly in the short term (46).  
 One potential disadvantage in grafting is 
AlloDerm’s lack of epidermis. The removal of this 
layer during processing is necessary since the 
epidermal cells are antigenic and stimulate rejec-
tion. The lack of “traditional epidermis” requires 
additional wound closure, typically achieved with 
a thin autograph. However, for large wounds, or 
cases in which the use of autograph is not pos-
sible or desired, other temporary dressing can be 
used to close the wound.
 It is important to inform the patient prior to sur-
gery of the source of the transplanted material. 
Some patients may be “repulsed” by the thought 
of cadaveric tissue being implanted into their bod-
ies (73). In a survey of religious leaders in the 
United Kingdom, 77% thought that prior to use pa-
tients should be informed of the constituents of a 
biological product, and that informed consent 
should be obtained (74).
 The product is fairly expensive at £5.90 per sq. 
cm (75). Driving the cost of the product is its inher-
ent reliance on human tissue, aseptic processing 
and the inability to perform terminal sterilization 
without compromising the integrity of the product’s 
matrix.
 AlloDerm is human tissue and the risk of dis-
ease transmission, particularly prion-related ill-
nesses such Creutzfeldt-Jacob (CJD) disease, 
cannot be said to be zero. To our knowledge there 
have been no known cases of transmissible infec-
tion with AlloDerm. The manufacturer adheres to 
strict donor acceptance criteria, maintains careful 
records, and follows the guidelines of the Ameri-
can Association of Tissue Banks. Further limiting 
risk, the donor skin processed into AlloDerm is not 
pooled. The risk of CJD transmission with non-
neurological tissue such as skin is believed to be 
quite low.
 In the future, AlloDerm may be utilized as a 
scaffold for the growth of cells to generate living 
tissue-engineered products (76,77). However, it is 
reported that cells proliferate mainly on the sur-
face of AlloDerm and do not penetrate the interior 
as well as on a synthetic matrix (76). The addition 
of an epithelial layer to obviate the need for a thin 
autograft would be a notable advance.  This ap-
proach has already been taken to produce con-
junctiva and an oral mucosa equivalent (59,78). 
Unfortunately, it is doubtful that the additional cost 
of these potential improvements could be borne 
commercially.  
 It is possible that eventually the same process 
used to render human cadaver skin non-antigenic 
can be applied successfully to porcine tissue, in a 
fashion allowing terminal sterilization. This would 
dramatically increase supply, drop costs, and po-
tentially expand the uses of dermal substitute. In 
recent animal studies using a porcine acellular 
dermal matrix (processed differently from Allo-
Derm), a robust immune response was observed 
with generally poor wound healing and significant 
contracture (79,80). New processing technologies 
will need to be developed to extend the success of 
AlloDerm to xenogeneic tissue.
 Integra Bilayer Matrix Wound Dressing – 
History and Description
 Integra Bilayer Matrix Wound Dressing (BMWD) 
is a two-layer membrane consisting of a cross-
linked bovine collagen/shark chondroitin-6-sulfate 
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layer, intended to mimic dermis, and an occlusive 
silicone outer layer which temporarily provides the 
sealant properties of epidermis.  The pore size of 
the collagen sponge dermal equivalent layer, at 
70-200 microns, is intended to promote cell migra-
tion. The collagen layer, after being placed on the 
wound, is infiltrated by fibroblasts that begin to lay 
down extracellular matrix and remodel the existing 
collagen. Over three to six weeks this layer takes 
on characteristics of true vascularized dermis (81). 
The synthetic outer layer is ultimately removed and 
replaced with a split thickness skin graft (STSG), 
as thin as 0.005 (82) or 0.006 inches in depth (83). 
Fang et al. found it impossible to harvest useful 
grafts of less than 0.005 inches (83). 
 Integra BMWD was developed in 1980 (84) at 
Harvard Medical School and Massachusetts In-
stitute of Technology, and subsequently licensed 
to Marion Laboratories Company. In 1990 the li-
cense was acquired by Integra Life Sciences Corp. 
(Plainsboro, New Jersey). In March 1996, the 
product was approved by the FDA for the postex-
cisional treatment of life-threatening full-thickness 
or deep partial-thickness thermal injury where 
sufficient autograft is not available at the time of 
excision or not desirable due to the physiological 
condition of the patient (85). The label was subse-
quently expanded, based on retrospective studies, 
to include “the management of wounds including: 
partial and full-thickness wounds, pressure ulcers, 
venous ulcers, diabetic ulcers, chronic vascu-
lar ulcers, surgical wounds (donor sites/grafts, 
post-Moh’s surgery, post-laser surgery, podiatric, 
wound dehiscence), trauma wounds (abrasions, 
lacerations, second-degree burns, and skin tears) 
and draining wounds” (85). Today, the device is 
widely used in burn surgery, including chemical 
(86,87) and electrical (86) injuries, and plastic and 
reconstructive applications.  
 Integra BMWD has a shelf life at room tem-
perature of two years, is available in a number of 
sizes, and is moderately expensive at £3.32 per 
sq. cm (75). BMWD appears to be well tolerated 
by the body and does not elicit rejection reaction 
(88) or significant inflammation (89).
Review of clinical applications
 Integra BMWD in burns
 Integra BMWD was initially reported in 1981 to 
have been successfully applied to a series of ten 
patients with full-thickness burns over 50%-90% 
of body surface area (90). By 1987 the product 
had been used in over 200 cases, in which it per-
formed similarly to autograft in closing postexci-
sion burn wounds (91). In the 149-subject pivotal 
clinical trial, in which BMWD and conventional 
care (either autograft, allograft, xenograft, or syn-
thetic wound covers) were assigned to matched-
pair sites on patients with full-thickness thermal 
injuries, the median take of BMWD was less than 
that of conventional autograft (80% vs. 95%) (92). 
These results were considered acceptable by clin-
ical investigators when consideration was given to 
overall management of the burn patient and the im-
mediate availability of BMWD. The use of BMWD 
was associated with less hypertrophic scarring 
and greater patient satisfaction. At six year follow 
up, BMWD retained its function and cosmetic ap-
pearance (91). However, Integra BMWD can be 
complex to use and the learning curve can be sub-
stantial. Not all early experiences with the product 
were positive (93).  
  Retrospective analysis of patients with mas-
sive burn injuries treated at Massachusetts Gen-
eral Hospital over a 12-year period, from 1974 to 
1986, suggests that the introduction of BMWD 
resulted in improved survival (94). But in a sub-
sequent retrospective analysis at Massachusetts 
General Hospital of 270 adult burn patients with 
greater than 20% TBSA involvement treated be-
tween 1992 and 2000, Integra BMWD had no ef-
fect on mortality. It did result in decreased hospi-
tal length of stay in the subgroup of patients with 
two or more mortality risk factors (63 days vs. 107 
days), but statistical analysis is hindered by the 
historical nature of the study (95). A post-approval 
216-patient, multicenter clinical trial in burn pa-
tients (mean TBSA 36.5%) was conducted to fur-
ther study the rate of infection with Integra BMWD 
(86). The mean and median take of Integra BMWD 
was 76.2% and 95%, respectively. The mean take 
of epidermal autograft was 87.7% with a median 
of 98%. This was superior to that seen in the 149-
patient pivotal trial (92), possibly due to adherence 
to the principles of complete excision and hemo-
stasis prior to Integra BMWD placement. Impor-
tantly, the rate of superficial and invasive infection 
was 13.2% and 3.1%, respectively.  
 BMWD has been used to close acute thermal 
injuries to the hand and for hand reconstructive 
procedures (96). Acute grafting was performed on 
15 hands (11 patients) with 100% take. At follow 
up (median of 12 month) the resulting skin was 
deemed flexible and supple without adherence to 
the deeper structures, allowing for good functional 
recovery. Cosmetic results were considered satis-
factory by both the patients and physicians. In re-
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constructive procedures on 14 hands (11 patients) 
significant improvements were achieved on the 
Vancouver Scar Scale and in several measures of 
hand function.   
 Serial surveys of 15 German burn centers con-
ducted in 1999, 2001 and 2003 suggest that the 
indications for Integra BMWD in burns has nar-
rowed over the years to full-thickness burns of 
greater than 50%-60% TBSA, in other words, to 
those patients in which primary wound closure 
cannot be achieved with split-thickness skin graft-
ing in the immediate post-injury period (97). Four 
of 15 centers had not used the product in the past 
two years due to high costs, uncertain outcomes, 
and the complicated and intensive care required in 
the interval between BMWD placement and split-
thickness skin grafting. 
 Adverse events reported in the pivotal clinical 
trial (92) included wound fluid accumulation, posi-
tive wound culture and clinical wound infection. 
The use of BMWD was associated with a higher 
rate of infected wound sites than the use of au-
tograft, resulting in these cases in partial or com-
plete loss of take. Other possible complications 
include shearing of the BMWD after application, 
graft loss, hematoma, silicone layer detachment, 
and incomplete epidermal graft take (98).  
 Careful attention to the wound during several 
weeks prior to STSG is therefore essential. The 
use of vacuum assisted closure in eight patients 
with complex wounds has recently been reported 
to result in accelerated vascularization of BMWD, 
an improved rate of take and therefore earlier skin 
grafting as compared to prior published results 
(99). This is consistent with a 12-patient random-
ized clinical trial comparing Integra BMWD alone 
(including negative-pressure preconditioning) with 
BMWD plus fibrin glue and negative-pressure 
therapy. Combination treatment resulted in an in-
creased take (98% vs. 78%) and decreased time 
to skin grafting (10 days vs. 24 days) (100).   
 Integra BMWD for plastic and reconstruc-
tive procedures
 In recent years BMWD has been more often 
used for plastic and reconstructive procedures 
where it enables coverage of large areas, resists 
contracture, promotes granulation and facilitates 
delayed autografting, even over avascular areas 
such as tendon, bone and cartilage. Important-
ly, BMWD does not adhere to these structures 
(98,101). In 23 elderly patients with scalp defects 
with exposed bone following cancer resection, In-
tegra BMWD was applied under local anesthetic 
followed by delayed skin grafting at an average 
time of 30 days (102). All patients achieved a 
closed wound with no evidence of exposed bone. 
However, infection complicated 21.7% of cases, 
necessitating replacement of the BMWD.  
 In two reported cases, Integra BMWD was 
used to close a wound in an irradiated scalp, an 
environment challenging due to impaired wound 
healing and compromised vasculature (103). The 
authors theorize that the ability of BMWD to vas-
cularize over several weeks enabled it to succeed 
where a skin graft, requiring vascularization within 
48-72 hours of placement, would probably have 
failed.
 A case study describing its use in immediate 
coverage of a large avulsion injury, followed by 
skin grafting, has been described (104), as well 
as successful resurfacing of a lower extremity fol-
lowing a latissmus dorsi free flap that had become 
unstable (105). It was used to cover a radial artery 
adipofascial free flap to the lower extremity, fol-
lowed by delayed skin grafting, with good cosmet-
ic outcome (106). Its successful use following can-
cer resection to cover nasal wounds with exposed 
cartilage, followed by split thickness skin grafting, 
has been reported in three case studies (107). In-
tegra BMWD has been used in the challenging ap-
plication of closing a radial forearm flap donor site 
over exposed tendon with take occurring in nine 
of ten cases (108). A case study has been report-
ed describing its use to close a forehead donor 
wound (109), a site that typically yields significant 
contour deformity. The authors concluded that the 
resultant appearance was a significant improve-
ment over the likely outcome of STSG applied di-
rectly to the periosteum.
 It was used in conjunction with STSG for clos-
ing the wound created by excision of giant hairy 
nevi in four pediatric patients (98); in conjunction 
with cultured autologous epithelium to cover the 
wound resulting from excision of a giant nevus on 
the back in a boy with neurocutaneous melanosis 
(110); and to achieve wound closure with STSG 
following excision of a giant congenital melanocyt-
ic nevi covering the entire back of an adult patient 
(111).   
 Release of post-burn injury contracture is an-
other area where BMWD is often used. Retro-
spective evaluation of BMWD in 89 consecutive 
patients (127 contracture release procedures) in-
dicated that at 76% of the release sites, the range 
of motion or function was rated by physicians as 
good or excellent. Patients expressed satisfaction 
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with the procedure at 82% of the sites. Seventy-
five percent of the sites were free from contracture 
recurrence during follow up (mean of 11.4 months) 
(112). As in prior studies, the most significant com-
plication observed with the use of BMWD was in-
fection or microbial colonization (20%), followed by 
fluid accumulation under the silicone layer (14%).
 In a series of 10 pediatric patients with upper 
extremity contractures reconstructed with BMWD, 
only six had an excellent outcome, whereas four 
had poor results (113). This was attributed by the 
authors to non-compliance with splinting on the 
part of the patients, highlighting the importance of 
postoperative care in this population.  
 In a series of 12 patients undergoing breast 
reconstruction and contracture release, the use 
of Integra BMWD plus a very thin (0.005 in.) epi-
dermal autograft resulted in durable improvement 
in breast contour and shape without clinically sig-
nificant recontracture within the follow up period 
(12 months) (82). Ninety-two percent of patients 
expressed a high degree of satisfaction with the 
outcome.  
 In 29 evaluable patients (37 wound sites) re-
ceiving Integra BMWD for various reconstructive 
applications, mostly burn scar revision, good re-
sults were achieved at 26 sites, average results at 
six, and poor results in three instances. The infec-
tion rate in this series was 12.8% (101). Using In-
tegra BMWD to close the wound, thirteen patients 
with prior burn injuries had successful contracture 
release of the upper extremity with no case of in-
fection (114).
 In the challenging indication of anterior neck 
contracture, Integra BMWD was initially success-
ful in five patients but contracture recurrence of 
greater than 50% occurred in all cases (115). This 
was attributed by the authors to the difficulty in 
achieving immobilization in this area. Successful 
use in neck contracture in a child has been report-
ed (116), but follow up for recontracture has not 
been published.
 It has been pointed out that in reconstructive 
procedures full vascularization of the neodermis 
takes four weeks and that STSG prior to this can 
result in delayed graft take (117). This is in con-
trast to the results in acute burns which indicate 
that vascularization of the BMWD is completed by 
two weeks (81). In fact, grafting beyond two weeks 
in burn patients is thought by some to contribute 
to over-granulation (115). Clinical examination of 
matrix color has been shown to correlate with the 
degree of vascularization (117), guiding clinical 
decision making.
 Integra BMWD in other skin disorders
Integra BMWD is useful in a variety of blistering, 
ulcerative, and purpuric disorders. Its use has 
been described in challenging chronic foot ulcers 
in two cases of Werner’s syndrome, a premature 
aging disorder (118); to reconstruct a large defect 
following excision of a squamous cell carcinoma 
in a patient with dystrophic epidermolysis bullosa 
(119); and to cover amputation sites in a case of 
purpura fulminans (120), a rapidly progressive 
hemorrhagic necrosis of the skin.  
 Integra BMWD – future directions
 The developers of BMWD pointed out them-
selves that one drawback of the product is its lack 
of permanent epidermal layer, ultimately necessi-
tating an autograft, albeit a thin one (121).  Seeding 
the bilayer membrane with autologous or heterolo-
gous epithelial cells before grafting is one alterna-
tive (122), as is sequential use of Integra BMWD 
and cultured cells. The consecutive use of Integra 
BMWD and cultured epidermal autograft (CEA) 
has been described in three patients, yielding 98% 
engraftment (123). A patient with 93% TBSA burn 
was treated with a combination of Integra BMWD, 
split-thickness skin graft and CEA (124), as was a 
15-year-old with 60% TBSA burns (125).  
 In a pig wound healing model, cultured autol-
ogous keratinocytes applied either to the under-
side of Integra BMWD or directly to the wound 
bed resulted in upward migration of keratinocytes 
through the matrix, yielding confluent surface epi-
thelium, but seeding onto the matrix was deemed 
more efficient (126). A novel approach uses a fi-
brin-based autologous cultured epithelium grafted 
onto the BMWD (127). This cultured epithelial 
construct is reported to have better handling char-
acteristics than those not cultured on fibrin. The 
addition of autologous cultured fibroblasts has 
also been described in one patient with 76% TBSA 
(128). In this case the use of BMWD in conjunc-
tion with autologus fibroblasts, keratinocyte sheets 
and 1:6 expanded skin grafts has been reported to 
provide best results in this patient as compared 
to any other combination of these modalities. Cul-
tured epidermal autograft has also been grown on 
fibroblast-seeded Laserskin (Fidia Advanced Bio-
polymers, Italy), a thin hyaluronic acid membrane 
that has been laser-perforated with microholes to 
facilitate ingrowth and proliferation of cells. This 
construct, termed Composite Biocompatible Skin 
Graft by its inventors, was grafted onto Integra 
BMWD in three patients with take ranging from 50 
to 100 percent (129,130). 
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 The addition of adnexal structures, notably hair 
follicles, to the Integra BMWD has been described 
in a patient with a large scalp burn (131). The re-
generated epidermis in this case was derived from 
stem cells in the hair follicle, but a sheet of autolo-
gous cultured keratinocytes was still required to 
achieve closure. 
 Despite the promise of cellular constructs 
based on or in conjunction with BMWD, the accel-
eration of healing observed by combining BMWD 
with negative pressure, as described above, will 
likely lower the impetus to pursue cellular modali-
ties commercially.
 Integra BMWD – summary and conclusion 
 Integra BMWD has proven useful in a wide va-
riety of burn injury, plastic and reconstructive pro-
cedures. It is readily available, stable to storage, 
well-tolerated and does not elicit a rejection reac-
tion. The use of the product is generally thought 
to result in superior skin cosmesis but not to the 
point of being equivalent to normal skin. Reduced 
donor site morbidity, a thinner STSG, faster donor 
site healing, and ability to re-crop donor site more 
often are important advantages.  
 The downsides of the product are notably 
wound fluid accumulation, positive wound culture 
and clinical wound infection, leading in some cas-
es to graft failure. The necessity for a second pro-
cedure (STSG) to definitively close the wound is a 
significant drawback, necessitating careful wound 
care in the several-week interim, a period fraught 
with opportunities for complications and graft fail-
ure. This, coupled with costs, has led some to 
abandon the product as noted above.    
 Although Integra BMWD plus cultured epithe-
lial autograft offers promise to ameliorate some 
of these problems, the high cost and logistical 
complexity of this combined procedure are likely 
to limit its adoption. The incorporation of signal-
ing peptides, such as RGD, or small molecule 
chemical mediators to accelerate Integra BMWD 
vascularization enabling more rapid STSG is one 
possible direction for improvement. In the near-
term the most promising improvement to Integra 
BMWD appears to be the addition of fibrin glue 
and negative pressure to accelerate take.
CONCLUSION
 Both AlloDerm and Integra BMWD are mem-
bers of the small family of commercially available 
dermal substitutes, which provide a three-dimen-
sional matrix to promote tissue regeneration, neo-
vascularization, host cell colonization and acceler-
ated healing. Both products are designed to deter 
wound contraction, which is a natural mechanism 
to reduce wound surface. This, otherwise, leads 
to scarring, poor cosmetics and impaired func-
tion. Integra BMWD also provides wound closure 
through its occlusive silicone layer.
 Although these products do not fulfill all of the 
requirements for an ideal skin substitute, they 
both have important applications in cases of se-
vere skin loss such as burns or large and deep 
wounds, and in other situations in which gold stan-
dards such as surgical wound closure (healing by 
primary intention) or autografting are not practical. 
Research and clinical development will likely yield 
new products and, by eliminating deficiencies, 
improve upon the existing ones. This gives hope 
to patients and physicians for continued improve-
ments in functional and cosmetic outcomes.
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